Jiri Damborsky and Team: Thrombolytic Proteins Profiling: High-Throughput Activity, Selectivity, And Resistance Assays
Jiri Damborsky, Head of Research Group at ICRC, Loschmidt Laboratories and Masaryk University, posted on LinkedIn:
”STROKE – Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop
Published: October 4, 2025, FEBS Open Bio.
Read here.
We introduce optimized high-throughput assays for rapid and reliable screening of thrombolytic enzymes – enabling detailed insights into activity, fibrin selectivity, and inhibition resistance.
Cardiovascular and thrombotic diseases remain one of the world’s top health challenges. In our latest work, we introduce a comprehensive set of high-throughput biochemical assays that enable robust screening and detailed characterization of thrombolytic biomolecules – including activity, fibrin selectivity, clot binding, and inhibition resistance.
Using alteplase and tenecteplase as model enzymes, we demonstrate how these assays can accelerate the development of safer and more effective thrombolytic drugs. Our results confirm that tenecteplase outperforms alteplase in fibrin selectivity and inhibition resistance, supporting its growing clinical relevance.”
Title: Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays
Authors: Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop
Stay informed with Hemostasis Today.
-
May 27, 2026, 13:10Amos Gitonga M: Global Partnerships Supporting Hemophilia and Sickle Cell Care in Africa
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK